[go: up one dir, main page]

WO2005096840A1 - Extraits de kiwi et procedes d'extraction - Google Patents

Extraits de kiwi et procedes d'extraction Download PDF

Info

Publication number
WO2005096840A1
WO2005096840A1 PCT/NZ2005/000071 NZ2005000071W WO2005096840A1 WO 2005096840 A1 WO2005096840 A1 WO 2005096840A1 NZ 2005000071 W NZ2005000071 W NZ 2005000071W WO 2005096840 A1 WO2005096840 A1 WO 2005096840A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
kiwifruit
juice
pulp
seed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NZ2005/000071
Other languages
English (en)
Inventor
Yi-Huai Gao
Jin Lan
Guo-Liang Chen
Quan Shu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DRAGON PACIFIC Ltd
New Zealand Institute for Bioeconomy Science Ltd
Original Assignee
DRAGON PACIFIC Ltd
New Zealand Institute for Crop and Food Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DRAGON PACIFIC Ltd, New Zealand Institute for Crop and Food Research Ltd filed Critical DRAGON PACIFIC Ltd
Publication of WO2005096840A1 publication Critical patent/WO2005096840A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
    • A23L19/01—Instant products; Powders; Flakes; Granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the invention relates to kiwifruit extracts and to a method of producing a kiwifruit extract from a kiwifruit.
  • Kiwifruit (Actinida) have been reported to be the most nutritionally dense of all commonly eaten fresh fruits. Several studies have demonstrated that consuming a certain amount of kiwifruit can be beneficial to humans and animals.
  • the invention provides a kiwifruit extract containing the following components:
  • the extract contains water-soluble polysaccharides, ⁇ -carotene and any one or more of alkaloid, ascorbic acid, tocopherol, folic acid, selenium, chlorophyll, arginine, or polyphenols, etc.
  • the components of the kiwifruit extract are present in the following amounts of the following bioactives, per 100 g of extract:
  • the extract includes, per 100 g of extract:
  • the extract contains at least about 15 mg polysaccharide per 100 g of extract.
  • the extract contains between about 15 mg and 80 mg of polysaccharide per
  • the kiwifruit extract has beneficial antioxidant, anti free radical, and immunological properties, and other health benefits related to kiwifruit components.
  • the kiwifruit extract is in a powder form.
  • the kiwifruit extract in powder form is mixed with a suitable carrier to produce a liquid or gel product.
  • the kiwifruit extract is mixed with a suitable carrier and forms part of a pill, tablet, or capsule.
  • the carrier is selected from any one or more of: polysaccharides, oligosaccharides, starches, sugars, glucans, gelatin, milk powder, liquid milk, proteins, lipids, fermented milk, fruit juice, and other suitable materials which can be used as a carrier, but not limited to these carriers.
  • the invention provides a process for producing a kiwifruit extract, the process including the following steps: ⁇ physical and enzyme treatment,
  • the temperature for drying the extract will be between 70°C and 80°C.
  • the process includes the steps of separation of kiwifruit pericarp and pulp, separation of kiwifruit seed and pulp, physical and enzyme treatments, dehydration, and drying of the extract.
  • the separation of the kiwifruit pericarp and pulp is achieved using a stainless steel net.
  • the stainless steel net is between 30 and 45 mesh, more preferably 40 mesh.
  • the separation of the kiwifruit seed and pulp is achieved using a stainless steel net.
  • the stainless steel net is between 250 and 350 mesh, more preferably 300 mesh.
  • the enzyme is pectinase and/or pepsin.
  • the invention relates to a product produced by the process of the second aspect of the invention, the product having beneficial antioxidant, anti-free radical, and/or immunological properties.
  • the invention provides a composition including a kiwifruit extract together with a suitable carrier, the kiwifruit extract including the following components: 1. water soluble polysaccharides; or
  • the extract contains at least about 15 mg polysaccharide per 100 g of extract.
  • the extract contains between about 15 mg and 80 mg of polysaccharide per 100 g of extract.
  • the carrier is a suitable pharmaceutical carrier which can be selected from any one or more of: polysaccharides, oligosaccharides, starches, sugars, glucans, gelatin, milk powder, liquid milk, proteins, lipids, fermented milk, or fruit juice, but not limited to these carriers.
  • the kiwifruit extract contains water-soluble polysaccharides, ⁇ -carotene and any one or more of alkaloid, ascorbic acid, tocopherol, folic acid, selenium, chlorophyll, arginine, polyphenols, and kiwifruit components.
  • the invention provides a method of producing a kiwifruit extract having beneficial antioxidant, immune, and anti-free radical properties from kiwifruit pericarp, seed and pulp by:
  • the invention provides a method for producing a kiwifruit extract, the method including the steps of
  • the seed when treated separately to the pulp is converted to a juice using acid and base treatment, followed by crushing and separation.
  • the enzyme treatments in steps (v) (a) and (v) (b) use different enzymes.
  • the invention is directed to kiwifruit extracts and their use in the manufacture of compositions that have beneficial effects on the health of the consumer, such as antioxidant, anti-free radical, and immunological properties, and other health benefits associated to bioactive components in kiwifruit.
  • beneficial effects include lower cholesterol, lower blood lipids, improvement of gut health (digestion, colon cancer) lower blood pressure, as well as wound healing effects, improved sleep and reduction of stress levels.
  • Health-promoting components of natural foods are of major medical and economic importance, and are the focus of considerable research internationally.
  • the nutriceutical market is developing rapidly to exploit the beneficial properties of components such as anti-oxidants (e.g., superoxide dismutase, vitamin C, vitamin E), polyphenols, polysaccharides, amino acids, fatty acids, and other bioactives.
  • anti-oxidants e.g., superoxide dismutase, vitamin C, vitamin E
  • polyphenols e.g., polyphenols, polysaccharides, amino acids, fatty acids, and other bioactives.
  • Kiwifruit contains many different bioactive components/chemicals and studies have shown that different kiwifruit (including Actinidia deliciosa, Actinidia chinensis, Actinidia arguta, etc from different parts of the world (including New Zealand and China)) are rich in ingredients such as water-soluble polysaccharide, ⁇ -carotene, tocopherol, ascorbic acid, folic acid, selenium, chlorophyll, arginine, polyphenols, actinidine, and peptides/proteins, etc.
  • ingredients such as water-soluble polysaccharide, ⁇ -carotene, tocopherol, ascorbic acid, folic acid, selenium, chlorophyll, arginine, polyphenols, actinidine, and peptides/proteins, etc.
  • Vitamin C promotes the biosynthesis of collagen and the growth of bone and teeth, functions in the maintenance of blood capillary walls, and prevents bleeding. It is closely related to the metabolism of tyrosine and tryptophan, accelerates deamination of proteins, and protects hydrophenylalanine oxidase. Vitamin C also cooperates with ATP and Mg to act as a co-activator of lipohydrolase. Vitamin C is an important free radical scavenger and functions with vitamin E and NADPH to prevent the oxidation of lipids and biological membranes. It enhances the absorption of Fe and Ca, activates the folic acid pathway, and promotes the response to "stress" from the environment. Above about 5000 ⁇ g of vitamin C per 100 g of extract is preferred.
  • ⁇ -carotene is a precursor of vitamin A, which participates in the constitution of rhodopsin and other light receptor pigments, promotes growth, and strengthens reproductive function. Moreover, ⁇ -carotene has roles in anti-oxidation and anti-free radical activity, extinguishing the single line form of oxygen, and functioning along with vitamin C and E to scavenge free radicals. Above about 100 ⁇ g of ⁇ -carotene per 100 g of extract is preferred.
  • Vitamin E can prevent oxidation of lipids, thus reducing the formation of lipoperoxide. It can also protect vitamins A and C, sulphur-containing enzymes, and ATP from oxidation and thus maintains their normal physiological functions. Vitamin E also increases the weight of thymus, stimulates B- and T cells, and modulates the biosynthesis of DNA. Above about 1 mg of vitamin E per 100 g extract is preferred.
  • Folic acid is important in the metabolism of amino acids, biosynthesis of proteins and nucleic acids, formation of porphyrins in red blood cells, production of white blood cells, metabolism of long chain fatty acids in the cerebrum, and synthesis of adrenaline and choline. Both vitamin C and folic acid may help prevent cardio-vascular diseases, such as coronary heart disease and cerebral thrombus, cancer, and deformity of the foetus. Above about 1000 ⁇ g of folic acid per 100 g extract is preferred.
  • Arginine is an essential component in the ornithine cycle, and has an important physiological role in the human body in maintaining the ammonia balance and normal growth. It is also a substrate for the formation of nitric oxide (NO) that is known to be an important physiological mediator. NO can activate macrophages and lymphocytes, and potentiate their ability to kill tumour cells and pathogens. Above about 1000 ⁇ g of arginine per 100 g extract is preferred.
  • Chlorophylls are the material basis of plant photosynthesis. They have anti-mutational effects by combining with carcinogenic substances such as aflatoxin and benzopyridine to form a complex. Chlorophylls inhibit allergic reactions and have anti-complement effects. They also accelerate wound and ulcer healing, and the growth of granulation. Above about 2500 ⁇ g of chlorophylls are preferred per 100 g extract.
  • Polyphenols include tannin and its derivative, catechin, and have properties of astringency, antibiosis, and preventing bleeding. Polyphenols decrease lipoperoxide levels, thus protecting cell membranes. Above about 4 ⁇ g of polyphenols are preferred per 100 g extract.
  • Ganoderma a medicinal mushroom (approximately 1.2%) from which polysaccharides are extracted and commercially sold in capsule form. Many polysaccharides arising from fruits and other plants have been shown to stimulate the immune system, activate effector cells such as macrophages and lymphocytes, and induce the production of cytokines such as tumour necrosis factor and interleukins. Above about 4 mg of water soluble polysaccharides per 100 g extract are preferred.
  • Selenium is a water-soluble anti-oxidant, acting as an essential part in glutathione oxidase. Se-containing proteins and organic selenium also exist in the human body, with selenium functioning along with vitamin E to scavenge free radicals. Animal studies have shown that selenium assists in the prevention of cancer and cardio-vascular diseases. Above about 4 ⁇ g of selenium per 100 g of extract is preferred.
  • Actinidine exists in an alkaloid form in kiwifruit. It has palliative and sedative effects on the central nervous system and notable influence on the sexual gland. Above about 4 ⁇ g of alkaloid per 100 g of extract is preferred.
  • kiwifruit extracts that include ⁇ water soluble polysaccharides; or « a combination of polysaccharides and alkaloid, ascorbic acid, tocopherol, folic acid, selenium, chlorophyll, arginine, polyphenols, or ⁇ -carotene, show beneficial effects associated with kiwifruit, including antioxidant, anti-free radical, immunological properties and other health benefits related to the presence of bioactive components in kiwifruit. It is preferred that the extract will include water-soluble polysaccharides and ⁇ -carotene together with one or more of the other listed components. As will be readily apparent, the extract will also contain other kiwifruit components not included in this list. Any strains of kiwifruit (Actinida) as would be known to the skilled person can be used to provide the extract.
  • Extracts which contain these combinations of components in suitable levels therefore have use in the preparation of compositions such as dietary supplements and in pharmaceutical products which are directed to the provision of benefits which are based on these properties.
  • the extracts themselves can be used directly, if desired, to benefit the consumer.
  • kiwifruit extracts can be used to manufacture a composition for administration to humans or animals (such as a kiwifruit extract capsule, drink, and other forms, or a kiwifruit extract additive in human foods/medicines or animal feed/veterinary medicines).
  • Compositions including extracts can comprise, for example, kiwifruit extracts in a pharmaceutically acceptable carrier.
  • carriers are suitable for use in this invention including polysaccharides, oligosaccharides, starches, sugars, glucans, gelatin, milk powder, liquid milk, proteins, lipids, fermented milk, fruit juice and other normal food/pharmaceutical ingredient carriers, etc.
  • the kiwifruit extracts can also be supplied as concentrates in an edible carrier.
  • Another alternative is to incorporate the kiwifruit extracts into a dry composition. Such compositions can be added to appropriate foodstuffs and/or pharmaceuticals.
  • Kiwifruit extracts can also be encapsulated directly as dietary supplements or made in cream form for use in wound care and cosmetic products as would be known to the skilled person.
  • Cosmetic formulations could be prepared as oil in water emulsions, water in oil emulsions, face lotions, cosmetic milk, gels, hydrogels, cremes, pomades, soaps, pellets, spraying materials, hair lotion and shampoos.
  • the extract may also be added to one or more cosmetic vectors, particularly one or more vectors selected from the group formed by liposomes, macrocapsules, microcapsules, nanocapsules, macro-particles, microparticles and nanoparticles.
  • the extract could be added in gel or liquid type form or powder form to dressings or could be included in antiseptic creams, for example.
  • novel foods/ pharmaceuticals can be made by incorporating the kiwifruit extracts into a variety of food/pharmaceutical carriers including:
  • the extraction procedure for producing a kiwifruit extract involves physical and chemical treatment including a combination of the general steps of separating kiwifruit pericarp and pulp, separating kiwifruit seed and pulp, physical and enzyme treatments, enzyme degradation prior to extraction of the extract, water and ethanol extraction, followed by drying the extracts. It is important that the extraction method does not inadvertently remove beneficial components. It is also advantageous if beneficial components in the kiwifruit and in the various parts of the kiwifruit can be retained in the extract as much as possible. .
  • the extraction procedure separates the pericarp from the remainder of the prepared kiwifruit using a stainless steel mesh or a similar type device. This will preferably be about 40 mesh but variations as would be known to the skilled person are possible.
  • the pericarp is subjected to treatment resulting in both pericarp juice and residue.
  • the press treatment preferably involves high press crushing of the pericarp.
  • the pericarp juice is collected and then dried, preferably by spray drying or freeze drying, to a powder form or can be mixed with other components prior to drying.
  • the residue can be discarded or, more preferably, can be treated to remove the chlorophyll component by acetone extraction or supercritical liquid extraction.
  • the treated pericarp residue and/or the chlorophyll component can be added to the final powder or saccharides contained in the pericarp residue extracted by hot water extraction. This is then dried and added to the powder.
  • the remainder of the kiwifruit (pulp and seed) can then be treated separately to the pericarp.
  • the pulp plus seed is preferably pulped or ground and then optionally treated with enzyme (preferably pepsin, pectatelyase, or pectinase) at a suitable temperature and time for the enzyme to take effect.
  • enzyme preferably pepsin, pectatelyase, or pectinase
  • the temperature should be between about 20°C and 30°C for a period of about 30 to 60 minutes.
  • the seed can be separated from the pulp, dehaired and subjected to treatment by acid (eg 1 N HCI) and base (eg 1 N NaOH) followed by washing, crushing and separation to produce a juice that is then dried to a powder.
  • acid eg 1 N HCI
  • base eg 1 N NaOH
  • the seed can also be ground and treated to extract lipids including vitamin E (eg ether extraction) and polysaccharides (hot water extraction), both of which can then be included in the final extract.
  • lipids including vitamin E (eg ether extraction) and polysaccharides (hot water extraction), both of which can then be included in the final extract.
  • the enzymes used will preferably be pectinase, pectatelyase, or pepsin. Alternative enzymes that achieve the same function could also be used if desired but would need to be selected to ensure that they did not otherwise interfere with the retention of the beneficial compounds in the extract. It is preferred that if two enzyme treatments are used, different enzymes are used in the two treatments.
  • the products of the extraction steps can be the powder or the juice. If juice then these can be mixed and then dried or used directly. If powder, they can simply be mixed together using known techniques.
  • the extraction process targets the beneficial components of the pericarp, pulp and seed of kiwifruit. It has been found that by doing this, extraction products of kiwifruit can be obtained that have desired beneficial effects.
  • the extracts can be used directly in pill/capsule type form, or added as a supplement to foodstuffs as discussed earlier.
  • the process provides an advantage to the user in that the extract that results from the process has a reduced loss of beneficial components and thus a heightened retention of the beneficial properties of kiwifruit including a heightened antioxidant, anti-free radical and immunological effect and other kiwifruit active related health benefits.
  • the ripe fruit has a better component make up and is preferably selected for use in the extraction procedure. It is, of course, possible to use unripe and stored fruit as well as the makeup is still satisfactory.
  • Example 2 Extraction procedures
  • the extraction procedures include the following major steps: cleaning and sterilizing kiwifruit, separating kiwifruit pericarp and pulp, separating kiwifruit seed and pulp, physical and enzyme treatments, enzyme degradation prior to extraction, water and ethanol extraction, and drying the extracts.
  • the following diagram shows a specific method (Process Flow) by which the required (or desired) components, including polysaccharides, ⁇ -carotene, tocopherol, ascorbic acid, folic acid, selenium, chlorophyll, glutamic acid, arginine, polyphenols and actinidine, can be extracted satisfactorily.
  • the individual steps of the extraction flow can be changed to produce different extracts with different or different proportions of bioactive components (each with different health-promoting properties) as desired.
  • the product produced can be tested to determine if the components fall within the desired ranges. If not, an alternative is selected. Alternatively a sample of the kiwifruit batch can be tested (eg as in Example 1). This is due to the variation that can occur between batches of kiwifruit. Process Flows are shown in Examples 2, 3 and 4.
  • MBP is bio-polymer derived from a marine organism, and used to precipitate protein
  • Processing flows (three ways) of production of kiwifruit extracts: ⁇ Processing flow (1) fruit
  • “Gaining weight” is the weight of dry powder obtained divided by kiwifruit weight.
  • Example 5 Health promoting effects of the kiwifruit extracts
  • Kiwifruit extracts were prepared using fresh kiwifruit, and were used in three trials using standard animal models. To identify extracts for each experiment the extracts were coded as follows: A1 : antioxidant/gold kiwifruit
  • A2 antioxidant/green kiwifruit
  • the invention in another aspect, includes kiwifruit extracts including the components and amounts substantially as shown in any one of Tables 5 to 7 above.
  • This dosage rate was used to calculate comparable rates for mice and rats based on mean body weight. For each of the three biological activities to be evaluated, different dose levels (low dose rate, 1.5 x low dose rate, 2 x dose rate, 4 x dose rate) were applied based on the 'intake dose' (set as the low dose rate) and 1.5, 2, or 4 multiples of that dose.
  • Animals were sourced from the Qingdao Animal Breeding Unit, Qingdao, China, and were housed within a 12 hour light/dark cycle at a controlled temperature and relative humidity with free access to water and food. After acclimatisation, animals were selected on the basis of live weight and randomised into different treatment groups. Different treatment groups were fed intragastrically on a daily basis with different dose rates of kiwifruit extracts dissolved in water. The control groups were treated with water only. The animals were maintained on the diets for 4 months. At the end of the treatment the rats were humanely killed, and blood and tissue samples were taken for analysis of the relevant parameters. Differences in parameter data were analysed using analysis of variance ANOVA (SPSS software 11.0).
  • Group 1 control; no kiwifruit extract
  • Group 2 low dose of extract A1
  • Group 3 low dose of extract A2
  • Group 4 2 x low dose of extract A1
  • Group 5 2 x low dose of extract A2
  • the parameters for measuring antioxidant activity were: superoxide dismutase (SOD), malondialdehyde (MDA), lipofasci (LPO) and glutathione peroxidase (GSH-Px).
  • SOD superoxide dismutase
  • MDA malondialdehyde
  • LPO lipofasci
  • GSH-Px glutathione peroxidase
  • Group 1 normal control, no kiwifruit extracts, no treatment
  • Group 4 low dose of extract B2, Fenton reaction Group 5: 2 x low dose of extract B1 , Fenton reaction
  • the Fenton reaction is used to generate free radicals
  • the parameters for measuring antioxidant activity were: SOD, MDA, fluorescence polarisation (P) and microviscosity ( ⁇ ) in rat erythrocyte membranes.
  • Group 2 low dose of extract Ci
  • Group 3 low dose of extract C2
  • Group 7 2 x low dose of extract C2
  • Group 8 4 x low dose of extract C1
  • Group 9 4 x low dose of extract C2
  • the parameters for measuring antioxidant activity were: phygocytic activity, lymphocytic proliferation/transformation, carbon clearance, and level of immunoglobulins (IgA, IgG, IgM).
  • the level of SOD in all animals fed with kiwifruit extracts was higher than that in rats not fed with kiwifruit (P ⁇ 0.05) (Table 1).
  • the GSH-Px activity in animals fed with the highest dose of kiwifruit extracts was also higher than in the control group (P ⁇ 0.05).
  • the levels of both MDA and LPO in all animals fed with the kiwifruit extracts were significantly lower than those in the control group (P ⁇ 0.05).
  • Significant differences in the parameters used to measure the antioxidant activity of golden and green kiwifruit extracts were not found (P > 0.05).
  • the MDA, P, and ⁇ were significantly increased in the experimental control group (Fenton treatment but no kiwifruit extracts fed) (P ⁇ 0.05).
  • the animals fed with different doses of kiwifruit extracts maintained the same (P > 0.05) or a significantly lower (P ⁇ 0.05) level of MDA, P, ⁇ (Table 2).
  • the level of SOD in all animals fed with kiwifruit extracts was also maintained at the same (P > 0.05) or higher (P ⁇ 0.05) level than the normal control (Table 2), while it was statistically significantly higher than in the experimental control (P ⁇ 0.05).
  • Significant differences in the parameters used to measure the free radical scavenging effects of golden and green kiwifruit extracts were not found (P > 0.05).
  • the experiments have well demonstrated a range of health benefits in the extracts of the components presented in kiwifruit.
  • the beneficial effects of kiwifruit have been well documented and include the antioxidant, anti-free radical and immunological benefits described in the Examples.
  • the extract also will exhibit other health benefits provided by the various bioactive compounds retained as a result of the extraction process. Some of these benefits have been described earlier in this specification (such as gut health, lower blood pressure, wound healing effect, etc).
  • the beneficial properties of kiwifruit in the extract can be suitably retained.
  • the ability to provide such a extract in powder or liquid form that can be provided to the consumer as discussed earlier is a significant advantage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Botany (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La présente invention concerne un procédé d'extraction de certains composants bioactifs du kiwi par le traitement du péricarpe, des graines et de la pulpe du kiwi et l'extrait produit par cette procédure d'extraction, cet extrait retenant des propriétés bénéfiques du kiwi dans une mesure souhaitable notamment des propriétés antioxydantes, anti-radicaux libres et des propriétés immunologiques.
PCT/NZ2005/000071 2004-04-08 2005-04-07 Extraits de kiwi et procedes d'extraction Ceased WO2005096840A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZNZ532254 2004-04-08
NZ532254A NZ532254A (en) 2004-04-08 2004-04-08 Kiwifruit extract and a method for producing powdered kiwifruit extract

Publications (1)

Publication Number Publication Date
WO2005096840A1 true WO2005096840A1 (fr) 2005-10-20

Family

ID=35124757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NZ2005/000071 Ceased WO2005096840A1 (fr) 2004-04-08 2005-04-07 Extraits de kiwi et procedes d'extraction

Country Status (2)

Country Link
NZ (1) NZ532254A (fr)
WO (1) WO2005096840A1 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118476A1 (fr) * 2005-04-29 2006-11-09 Vital Food Processors Limited Huile de kiwi et procede d'extraction
WO2006119553A1 (fr) * 2005-05-06 2006-11-16 R & J Thumm Pty Ltd Procede et appareil pour extraire des jus de vegetaux impliquant l'extraction de bionutriments a partir de la peau, des graines, de la pulpe, d'autres solides de ces vegetaux
EP1967079A3 (fr) * 2007-03-08 2008-11-12 Probelte Pharma, S.A. Processus et appareil pour préparer des extraits de grenade
WO2008136689A1 (fr) * 2007-05-03 2008-11-13 Vital Food Processors Limited Compositions à base de kiwi
WO2010056675A3 (fr) * 2008-11-12 2010-07-22 June Jacobs Laboratories, Llc Compositions antioxydantes pour la purification et le conditionnement de la peau
WO2012078587A1 (fr) * 2010-12-07 2012-06-14 University Of Oslo Agents cardioprotecteurs provenant des kiwis
DE102012013531A1 (de) * 2012-07-05 2014-01-09 Iduso Gmbh Rohes Kiwimus als Gefriergut
CN106083857A (zh) * 2016-06-06 2016-11-09 大连民族大学 一种从软枣猕猴桃中提取叶酸的方法
EP2709641B1 (fr) * 2011-05-16 2017-12-13 Vital Food Processors Limited Complément alimentaire
CN108497262A (zh) * 2018-03-23 2018-09-07 贵州理工学院 一种快速分离获取火龙果籽的方法
CN110563686A (zh) * 2019-09-17 2019-12-13 西北大学 一种软枣猕猴桃根提取物、提取分离方法及其应用
CN110710679A (zh) * 2019-11-22 2020-01-21 烟台新时代健康产业有限公司 一种具有抑制前列腺癌细胞增殖迁移作用的松花粉组合物
CN111307973A (zh) * 2020-03-09 2020-06-19 西北农林科技大学 一种猕猴桃果汁结合态香气物质释放的方法
CN114561108A (zh) * 2022-04-21 2022-05-31 四川省自然资源科学研究院(四川省生产力促进中心) 一种猕猴桃中类胡萝卜素提取工艺
CN115745886A (zh) * 2022-12-07 2023-03-07 佳木斯大学 一种基于软枣猕猴桃制取生物碱的工艺
CN115997793A (zh) * 2023-02-13 2023-04-25 贵州大学 一种猕猴桃果实提取物、制备方法及应用

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112568437B (zh) * 2020-12-04 2023-01-20 恩施土家族苗族自治州农业科学院(恩施土家族苗族自治州硒应用技术与产品开发研究院) 一种富硒青钱柳中硒多糖的提取方法和由该提取方法得到的硒多糖及其应用
CN112919989A (zh) * 2021-01-20 2021-06-08 重庆文理学院 一种适用于富硒猕猴桃生产的肥料及其制备方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0272850A (ja) * 1988-09-06 1990-03-13 Ehime Pref Gov Seika Nogyo Kyodo Kumiai Rengokai キウイフルーツ透明果汁の製造法
EP0395822A1 (fr) * 1989-05-03 1990-11-07 S.I.C.A.R.E.X. De L' Espiguette Procédé de fabrication d'une boisson pétillante faiblement alcoolisée à base de kiwi
WO1991003172A1 (fr) * 1989-09-07 1991-03-21 Commonwealth Scientific And Industrial Research Organisation Produits a base de kiwis
WO2001070259A1 (fr) * 2000-03-21 2001-09-27 Bruce William Donaldson Ameliorations relatives a des compositions digestives-laxatives
WO2003103415A1 (fr) * 2002-06-07 2003-12-18 Ann De Wees Allen Nouvelles compositions d'edulcorant et procedes d'utilisation
US20040037909A1 (en) * 2002-08-23 2004-02-26 Kim Bong Cheol Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0272850A (ja) * 1988-09-06 1990-03-13 Ehime Pref Gov Seika Nogyo Kyodo Kumiai Rengokai キウイフルーツ透明果汁の製造法
EP0395822A1 (fr) * 1989-05-03 1990-11-07 S.I.C.A.R.E.X. De L' Espiguette Procédé de fabrication d'une boisson pétillante faiblement alcoolisée à base de kiwi
WO1991003172A1 (fr) * 1989-09-07 1991-03-21 Commonwealth Scientific And Industrial Research Organisation Produits a base de kiwis
WO2001070259A1 (fr) * 2000-03-21 2001-09-27 Bruce William Donaldson Ameliorations relatives a des compositions digestives-laxatives
WO2003103415A1 (fr) * 2002-06-07 2003-12-18 Ann De Wees Allen Nouvelles compositions d'edulcorant et procedes d'utilisation
US20040037909A1 (en) * 2002-08-23 2004-02-26 Kim Bong Cheol Composition comprising the extract of actinidia arguta and related species for the prevention and treatment of allergic disease and non-allergic inflammatory disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199016, Derwent World Patents Index; Class D13, AN 1990-121026 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006118476A1 (fr) * 2005-04-29 2006-11-09 Vital Food Processors Limited Huile de kiwi et procede d'extraction
WO2006119553A1 (fr) * 2005-05-06 2006-11-16 R & J Thumm Pty Ltd Procede et appareil pour extraire des jus de vegetaux impliquant l'extraction de bionutriments a partir de la peau, des graines, de la pulpe, d'autres solides de ces vegetaux
EP1967079A3 (fr) * 2007-03-08 2008-11-12 Probelte Pharma, S.A. Processus et appareil pour préparer des extraits de grenade
WO2008136689A1 (fr) * 2007-05-03 2008-11-13 Vital Food Processors Limited Compositions à base de kiwi
WO2010056675A3 (fr) * 2008-11-12 2010-07-22 June Jacobs Laboratories, Llc Compositions antioxydantes pour la purification et le conditionnement de la peau
WO2012078587A1 (fr) * 2010-12-07 2012-06-14 University Of Oslo Agents cardioprotecteurs provenant des kiwis
US9987317B2 (en) 2010-12-07 2018-06-05 University Of Oslo Cardio-protective agents from kiwifruits
EP2709641B1 (fr) * 2011-05-16 2017-12-13 Vital Food Processors Limited Complément alimentaire
DE102012013531A1 (de) * 2012-07-05 2014-01-09 Iduso Gmbh Rohes Kiwimus als Gefriergut
CN106083857A (zh) * 2016-06-06 2016-11-09 大连民族大学 一种从软枣猕猴桃中提取叶酸的方法
CN108497262A (zh) * 2018-03-23 2018-09-07 贵州理工学院 一种快速分离获取火龙果籽的方法
CN110563686A (zh) * 2019-09-17 2019-12-13 西北大学 一种软枣猕猴桃根提取物、提取分离方法及其应用
CN110710679A (zh) * 2019-11-22 2020-01-21 烟台新时代健康产业有限公司 一种具有抑制前列腺癌细胞增殖迁移作用的松花粉组合物
CN111307973A (zh) * 2020-03-09 2020-06-19 西北农林科技大学 一种猕猴桃果汁结合态香气物质释放的方法
CN114561108A (zh) * 2022-04-21 2022-05-31 四川省自然资源科学研究院(四川省生产力促进中心) 一种猕猴桃中类胡萝卜素提取工艺
CN115745886A (zh) * 2022-12-07 2023-03-07 佳木斯大学 一种基于软枣猕猴桃制取生物碱的工艺
CN115997793A (zh) * 2023-02-13 2023-04-25 贵州大学 一种猕猴桃果实提取物、制备方法及应用
CN115997793B (zh) * 2023-02-13 2025-03-07 贵州大学 一种猕猴桃果实提取物、制备方法及应用

Also Published As

Publication number Publication date
NZ532254A (en) 2006-03-31

Similar Documents

Publication Publication Date Title
RU2387136C2 (ru) Первичная композиция для обеспечения организма функциональными ингредиентами, способ ее приготовления и применение (варианты), композиция для перорального употребления (варианты)
WO2005096840A1 (fr) Extraits de kiwi et procedes d'extraction
US8496977B2 (en) Natural extract from whole banana fruit (Musa Spp)
CN112998168B (zh) 一种透明质酸复合多肽饮品及其制备方法
US11564952B2 (en) Water-soluble and water-insoluble propolis products with high antioxidant capacity and their production methods
JP7587877B2 (ja) 組成物
CN107669731A (zh) 一种护肤组合物及其应用、保健品
JP2010265251A (ja) 血流促進改善剤
JP2007204423A (ja) ササ抽出物の製造方法及び該抽出物の利用
EP4096430A1 (fr) Produits améliorés dérivés de bananes vertes ou de bananes plantains
JP5597828B2 (ja) 育毛剤
JP2015110536A (ja) 疲労改善組成物
JP7016510B2 (ja) 血中コレステロール上昇抑制組成物
JP6757995B2 (ja) 経口組成物
JP2010537670A (ja) 新生家畜においてｔ細胞免疫調節を調整するためのモリンダ・シトリフォリア系製剤
CN102065878A (zh) 使用海巴戟天种子油的制剂和方法
KR20170065956A (ko) 육계나무 수피 추출물을 포함하는 항산화 또는 항염증 조성물
JP2007131579A (ja) 生理活性組成物及びその製造方法
JP7562169B2 (ja) 血中コレステロール上昇抑制組成物
Schappo et al. Trends in the full use of the superfruit Psidium guajava: a scientific and technological review
JP2023182356A (ja) エリスロポエチン産生促進剤
JP2022115615A (ja) Ｎｋ細胞活性化組成物
JP2022050660A (ja) 血中コレステロール上昇抑制組成物
RU2635575C1 (ru) Пищевая добавка
JP2024103775A (ja) 経口組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase